Webcast to Provide Company Update on March 5, 2024
VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold on leronlimab. The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation.
CytoDyn's CEO, Dr. Jacob Lalezari, stated, "We are excited that the clinical hold on leronlimab has been lifted by the FDA. CytoDyn is grateful for the FDA's guidance on our protocol and we are excited to open a new chapter in the development of leronlimab as a therapy that provides clinical benefit by modulating chronic inflammation."
Dr. Lalezari will host an investment community webcast to provide a Company update on Tuesday, March 5, 2024. The update will include a discussion about the Company's clinical trial goals and expectations, upcoming publications, and overall development strategy moving forward.
Date: Tuesday, March 5, 2024
Time: 9:00 am PT / 12:00pm ET
Access: https://event.choruscall.com/mediaframe/webca...d=KP5IRea9
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until at least April 5, 2024. The Company will not be conducting a Q&A session on this update call. However, please feel free to submit your questions to the Company via email to: ir@cytodyn.com.
VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold on leronlimab. The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation. CytoDyn's CEO, Dr. Jacob Lalezari, stated, "We are excited that the clinical hold on leronlimab has been lifted by the FDA. CytoDyn is grateful for the FDA's guidance on our protocol and we are excited to open a new chapter in the development of leronlimab as a therapy that provides clinical benefit by modulating chronic inflammation."
Dr. Lalezari will host an investment community webcast to provide a Company update on Tuesday, March 5, 2024. The update will include a discussion about the Company's clinical trial goals and expectations, upcoming publications, and overall development strategy moving forward.
Date: Tuesday, March 5, 2024
Time: 9:00 am PT / 12:00pm ET
Access: https://event.choruscall.com/mediaframe/webca...d=KP5IRea9
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until at least April 5, 2024. The Company will not be conducting a Q&A session on this update call. However, please feel free to submit your questions to the Company via email to: ir@cytodyn.com.
10
